Lumexa Imaging Holdings, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LMRI research report →
Range $13 – $19
Price Chart
About the company
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography.
- CEO
- Caitlin Zulla
- IPO
- 2025
- Employees
- 5,000
- HQ
- Raleigh, NC, US
Get TickerSpark's AI analysis on LMRI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.37B
- P/E
- -54.00
- Fwd P/E
- 16.35
- PEG
- -1.43
- P/S
- 1.29
- P/B
- 2.15
- EV/EBITDA
- 20.75
- Div Yield
- 0.00%
- Gross Margin
- 12.28%
- Op Margin
- 0.64%
- Net Margin
- -1.61%
- ROE
- -2.80%
- ROIC
- 0.40%
Latest fiscal year · YoY change
- Revenue
- $1.02B+7.8%
- Gross Profit
- $117.19M+21.7%
- Op Income
- $26.73M
- Net Income
- $-47,104,000+49.9%
- EPS
- $-0.66+34.0%
- OCF Growth
- -58.1%
- FCF Growth
- -149.4%
- 52W High
- $19.45
- 52W Low
- $6.45
- 50D MA
- $11.68
- 200D MA
- $11.11
- Beta
- 0.99
- RSI (14)
- 63
- Avg Volume
- 373.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Lumexa posted solid Q3 growth, record advanced-modality mix, and stronger cash flow, while narrowing full-year EBITDA guidance and raising EPS guidance.· November 10, 2026
- Consolidated revenue was $272 million, up 5% year over year; adjusted EBITDA was $62.6 million, up 11% from Q3 2025, with margin at 23.0%.
- Advanced modalities hit a record 38.2% of systemwide volume, up 145 basis points year over year, and PET grew 19.5% year over year.
- Free cash flow improved to $20.6 million from negative $1.8 million a year ago; management now expects free cash flow conversion of at least 30% for 2026.
- The company opened 3 new De Novo centers in early November and still expects 8 to 10 De Novo openings in 2026.
- Lumexa expanded its JV with Advocate Health into Illinois and said its site-neutral opportunity meaningfully expands the addressable market over time.
Q3 consolidated revenue was $272 million, up 5% year over year. Outpatient net patient service revenues were $149 million, up 5.5%; professional fee net patient service revenues were $62.1 million, up 2.6%; and management fee and other revenues were $60.9 million. Adjusted EBITDA was $62.6 million, up from $59.1 million a year ago, with adjusted EBITDA margin of 23.0% versus 22.8% last year. GAAP EPS was $0.07 and adjusted EPS was $0.26. Free cash flow was $20.6 million versus negative $1.8 million in Q3 2025, and cash from operating activities was $34.8 million. Full-year guidance was narrowed: adjusted EBITDA to $236 million to $240 million, consolidated revenue reiterated at $1.045 billion to $1.097 billion, and adjusted EPS raised to $0.86 to $0.90 from $0.71 to $0.77. Management also said 2026 free cash flow conversion is now expected to be at least 30%.
Caitlin Zulla emphasized that Lumexa is executing its strategy of building a lower-cost outpatient imaging platform through same-center growth, advanced imaging mix, De Novos, and health-system partnerships. She highlighted record advanced-modality penetration, the new Advocate Health expansion into Illinois, and the opening of 3 new centers in November. Her tone was confident and constructive, especially around site-neutral reimbursement, which she said should support more outpatient imaging migration over time.
Tony Martin said the quarter showed strong operating leverage, with adjusted EBITDA up 11% sequentially to $62.6 million and margin improving 160 basis points sequentially. He pointed to interest expense of $15.7 million, down about $14 million from Q3 2025 due to debt paydown, and cash on hand of $90 million at quarter-end, with net leverage at 3.5x versus 5.6x a year ago. He also noted G&A of $30 million, about $12.9 million higher year over year, driven by public-company costs and stock-based compensation, and said 2026 stock comp should be about $50 million, with ongoing 2027 stock comp expected at $20 million to $28 million. He reiterated disciplined but somewhat higher CapEx as the company leans into De Novos and targeted investments.
Analysts pressed on whether elevated CapEx is mostly tied to advanced modalities and how quickly it translates into volume, and management said investments are going toward FastScan, PET upgrades, and De Novo openings, with strong demand for advanced procedures. Questions also focused on the lower center count, and management said it sometimes consolidates centers to maintain density and market quality. On the site-neutral rule, management said it could broaden JV opportunities and potentially lead some hospital outpatient departments to be recredentialed as IDTFs, but the impact should unfold over years rather than quarters.
The call showed accelerating mix toward higher-reimbursing advanced modalities, with record systemwide penetration and strong PET growth. Cash generation also improved meaningfully, and management raised EPS guidance while narrowing EBITDA guidance, signaling confidence in execution and limited near-term reimbursement impact.
Growth still depends on continued CapEx, De Novo ramping, and successful JV expansion, which can take time to convert into results. Management also flagged slightly worse-than-expected Medicare reimbursement assumptions and said the site-neutral tailwind will unfold over years, not quarters, so some of the market opportunity remains longer dated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 96.12M
- Float Shares
- 95.72M
of shares held by institutions
104 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Brown Advisory Inc | 6.62M | ▲ 843.62K |
| Massachusetts Financial Services Co | 2.95M | ▼ 507.73K |
| Jupiter Topco LLC | 2.15M | ▲ 2.15M |
| Think Investments LP | 2.11M | ▼ 454.44K |
| Brooklands Fund Management Ltd | 2.11M | ▲ 2.11M |
| Silvercrest Asset Management Group LLC | 1.55M | ▲ 1.09M |
| Blackrock, Inc. | 1.40M | ▼ 2.68K |
| Janus Henderson Group Ltd. | 1.18M | ▲ 1.18M |
| Vanguard Capital Management LLC | 1.07M | ▼ 2.44K |
| Royce & Associates LP | 988.52K | ▲ 199.48K |
| Punch & Associates Investment Management, Inc. | 905.95K | ▲ 905.95K |
| Brigade Capital Management, LP | 852.81K | ▲ 186.91K |
Held by 101 ETFs
Biggest fund positions in LMRI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Mittl Robert Louis Jr. | other | 19,358 |
| Jun 10, 26 | Lungren Matthew | other | 19,358 |
| Jun 10, 26 | Karlin Bridget E | other | 19,358 |
| Jun 10, 26 | Joseph Molly | other | 19,358 |
| Jun 10, 26 | EISENBERG GLENN A | other | 19,358 |
| Jun 10, 26 | Cooper Henry Lee | other | 19,358 |
| Jun 10, 26 | BRODNAX BRETT | other | 19,358 |
| May 19, 26 | BRODNAX BRETT | buy | 35,000 |
| May 14, 26 | Cooper Henry Lee | buy | 30,000 |
| Feb 25, 26 | Walker James Edward Jr. | other | 12,414 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LMRI coverage
Recent articles, reports, and earnings notes.
No research on LMRI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LMRI report →How Much Upside is Left in Lumexa (LMRI)? Wall Street Analysts Think 30.84%
zacks.com · Nov 19
Why Lumexa (LMRI) Might be Well Poised for a Surge
zacks.com · Nov 17
Lumexa Imaging Opens Three New Imaging Centers in November
globenewswire.com · Nov 16
Lumexa Imaging Expands Partnership with Advocate Health Through New Illinois Joint Venture
globenewswire.com · Nov 12
Lumexa Imaging Holdings, Inc. (LMRI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
What Lumexa Imaging (LMRI) Said on Its Q3 Earnings Call
marketbeat.com · Nov 10
Lumexa Imaging Announces Third Quarter 2026 Results
globenewswire.com · Nov 10
Lumexa Imaging Announces Third Quarter 2026 Earnings Conference Call Date
globenewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.